A successful presentation of a First-in-Class drug targeting ‘BTN1A1’ at the AACR 2021 관리자 │ 2021-04-16 HIT 267544 |
---|
- STCube presented preclinical data of ‘hSTC810’, a
First-In-Class antibody product targeting ‘BTN1A1’, at the American Association
for Cancer Research (AACR) The
company’s novel drug targeting ‘BTN1A1’ was successfully presented at the AACR
poster session.
‘BTN1A1’
is an immune checkpoint protein that suppresses the proliferation of CD8+ T
cells, which normally acts to inhibit the growth of tumor cells. The protein is
highly expressed in solid tumors that poorly respond to immunotherapies
targeting PD-1/PD-L1.
Using
a self-developed IHC antibody, STCube showed that ‘BTN1A1’ is highly
expressed in tumor cells of the squamous cell carcinoma (56.3%), head and neck
(84.5%), bladder cancer (75%), and breast cancer (63.2%). In particular, the
protein shows a high expression rate of 56.1% in ovarian cancer in which PD-L1 is
known to rarely express.
In
addition, it was confirmed through OPAL staining that the expressions of ‘BTN1A1’
and PD-L1 are mutually exclusive. This implies that ‘BTN1A1’ is a novel immune
checkpoint protein distinct from PD-1/PD-L1.
The
company plans to initiate global clinical trials upon obtaining IND approval
from US food and Drug Administration (FDA) in the second half of this year. Various development options, including co-development
with and/or licensing out to multinational pharmaceutical companies, are being
explored at the current time.
STCube’s
presentation in the AACR 2021 can be viewed by downloading the attached
file.
|
Prev | Research on STCube’s Small Molecule Immunotherapeutic Agent for Pancreatic Can... |
---|---|
Next | STcube, Selected by Pharma Tech Outlook TOP 10 Immunotherapy Solution Companies |